Objective. The treatment of relapsed and refractory multiple myeloma (RRMM) remains challenging. The outcomes in highly pretreated populations are unsatisfactory and there is urgent need for novel and safe therapeutic approaches. Recently, daratumumab has been approved for RRMM with promising results even in monotherapy. The aim of this study was to assess the efficacy of single agent daratumumab outside a clinical trial. Patients and Methods. 14 patients with RRMM and significant pretreatment (median 4.5 previous lines) entered a specific healthcare program and received treatment with single agent daratumumab. They were followed for therapeutic response based on IMWG criteria, and incidence of adverse events. The data were collected using the Registry of Monoclonal Gammopathies. Results. The overall response rate was 38.5%. 23.1% of patients reached very good partial response, 15.4% reached partial remission, 15.4% had minimal response, 38.5% had stable disease and 7.7% had progressive disease. The median progression free survival was 4.6 months and median overall survival was not achieved. The toxicities were mostly mild, only infectious complications and hematological toxicity reached grade III. Conclusion. We conclude that daratumumab has significant activity in highly pretreated RRMM even as a single agent, with an acceptable toxicity profile and survival impact.
INTRODUCTION
Daratumumab (DARA) is an anti-CD38 monoclonal antibody (mAb) recently introduced in the treatment of relapsed or relapsed and refractory multiple myeloma (MM). DARA targets myeloma cells via a variety of immune-mediated mechanisms including complementdependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and direct apoptosis with crosslinking 1, 2 . DARA was originally chosen from a large panel of anti-CD38 mAbs because of its ability to trigger complement-dependent cytotoxicity 3 . Another mechanism of action -immunomodulatory -has recently been discovered. This though still not fully understood, is probably based on depletion of CD38+ immune suppressive cells such as Tregs, Bregs or myeloid derived suppressor cells 1 . DARA was approved by the US Food and Drug Administration (FDA) as a single agent for advanced MM, based on the results of the phase II trial SIRIUS 4 .
In the SIRIUS trial, DARA was used as a single agent treatment for advanced multiple myeloma. Even in this setting of highly pre-treated MM (median previous treatment lines was 5) it had considerable treatment response with prolongation of progression free survival (PFS) and overall survival (OS).
Based on the SIRIUS trial, a state based healthcare program (54767414MMY4001) was introduced into the Czech Republic in March 2016 to assess the efficacy of DARA in a "real world" setting. We present the results of the program.
PATIENTS AND METHODS
The healthcare program was registered at the Ministry of Health of the Czech Republic under the identification code 54767414MMY4001. The program was conducted under the aegis of the Czech State Institute for Drug Control (SUKL -Státní Ústav pro Kontrolu Léčiv) and carried out at 7 hematological centres in the Czech Republic. Altogether, a maximum of 14 patients were intended for recruitment and a maximum of 2 patients at each centre. The inclusion criteria followed FDA approval criteria, ie. "DARZALEX is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent."(ref. 5 ).
The patients received daratumumab monotherapy according to the schedule of SIRIUS trial: DARA 16 mg/ kg i.v. per week for 8 weeks (cycles 1 and 2), then every 2 weeks for 16 weeks (up to cycle 6), and every 4 weeks thereafter. First infusions were 1000 mL at 50 mL/h, followed by dose escalation up to 200 mL/h. Second and subsequent infusions were 500 mL at 100 mL/h with an increase to 200 mL/h. Standard premedication was used before DARA administration: methylprednisolone 100 mg intravenously for the first and second infusions and 60 mg thereafter, or equivalent (mostly we used dexamethasone 16-40 mg), paracetamol 650-1000 mg and an antihistamine drug according to local guidelines. The data were collected using the Registry of Monoclonal Gammopathies (RMG), a large multicenter database for collecting the data of MM patients within Central Europe 6 .
RESULTS
Despite a very short recruitment period (practically within one month), all 14 patients were recruited and started DARA treatment. The basic demographics, group and disease characteristics were standard and are summa-rized in Table 1 . Median age was 60.5 years with an even distribution of males and females. Most of the patients were ECOG 1 (8/14 patients, 57.1%), followed by ECOG 0, 2 and 3 (in 2/14 patients each, 14.3%). ISS stage at the time of relapse before DARA treatment was assessed in 12 patients, most of them being stage 3 (42.9%), followed by ISS 1 and 2 (both 21.4%). The initial ISS (at the time of MM diagnosis) was assessed in all patients, and was as follows: ISS 1 in 7/14 patients (50%), ISS 2 in 4/14 patients (28.6%) and ISS 3 in 3/14 patients (21.4%). The patients had mildly elevated levels of creatinine (median 113 umol/L, up to 250 umol/L) and 21.4% of patients (3/14) had extramedullary disease, with a significant percentage of patients having high-risk cytogenetic features, t(4;14) in 5/7, del17 in 1/6, del13 in 7/8 and amp1q21 in 3/6 patients. The median previous lines was 4.5 (2-8), 93% of patients had previous autologous stem cell transplant (ASCT), all received previous bortezomib, most of them received lenalidomide (86%) and thalidomide (64%), and a significant percentage received pomalidomide (50%) and carfilzomib (21%). Two thirds of the patients were refractory to their last line of treatment before DARA. Median follow up for the whole cohort was 8 months.
The treatment responses and intervals are shown in Table 2 together with indirect comparison with the SIRIUS trial. The overall response rate (ORR) was 38.5% with 23.1% of patients reaching very good partial response (VGPR) or better, 15.4% reached partial remission (PR), 15.4% of SD patients had minimal response (MR), 38.5% had stable disease (SD), and 7.7% had progressive disease (PG). The overall PFS was 4.6 months and median OS was not reached (Fig 1) 
DISCUSSION
DARA was approved based on a phase II clinical trial (SIRIUS) as a breakthrough therapy, which is quite rare as most drugs have to confirm their efficacy in phase III trials. Even in the setting of highly pre-treated MM (median previous treatment lines was 5 with most patients being double or triple refractory to proteasome inhibitors and immunomodulators) DARA had substantial treatment response (ORR = 29.2%) with prolongation of PFS (3.7 months in the whole cohort, 15 months in DARA responders) and overall survival (median OS not reached, after longer follow-up OS = 20 months) (ref. 4 ). Other recently approved drugs such as elotuzumab or panobinostat 7, 8 ). Moreover, adjusted comparison of real world data from RMG with pooled analysis of daratumumab monotherapy confirmed the same finding 9, 10 . The treatment of advanced stage MM is very exacting. Patients usually experience adverse events from previous treatments, and may have limited bone marrow reserves. Moreover, after several different therapeutic regimens, the underlying MM clone that causes relapse is usually more aggressive and resistant to multiple drug classes. Emerging new treatments are therefore needed to target different pathways and overcome the resistance of the clone. The effectiveness of any single agent is therefore very encouraging in late stage MM but it has to be confirmed by further trials as well as in routine practice. Steroids are among the most effective drugs in MM treatment, especially in combination regimens. Their efficacy as monotherapy in late stage MM is, however, very limited. In a recent review of DARA trials, the drug was evaluated as generally well tolerated as monotherapy and with a manageable tolerability profile when used in combination therapy 11 .
The outcomes of two other phase III clinical trials, CASTOR and POLLUX, that combined daratumumab with bortezomib or lenalidomide and A in a relapsed setting revealed an unprecedented efficacy of the combined regimens 12, 13 . The combination of DARA with other agents definitely has better potential to control the disease than monotherapy but the economic burden of the combinations is not negligible. A single dose of DARA exceeds 7000 USD: Hence, the total cost is highest in the first two months with weekly dosing, decreasing with further treatment with reduced frequency of dosing (once per 14 days cycles 3-6, once per month thereafter). The cost of combined regimens is increased accordingly. However, recent updates of CASTOR and POLLUX trials after longer follow-up confirm significant benefits with respect to PFS, ORR and depth of response including the rate of minimal residual disease (MRD), with no further safety issues, justifying the increased costs of these regimens 14, 15 . Moreover, patients relapsing in the DARA arm responded more favorably to subsequent therapy 15 . It is very likely that DARA plays a similar role in MM treatment as rituximab in B-cell non-Hodgkin lymphomas. Currently, DARA is being tested in first line treatment and even in smoldering MM with very promising results 16, 17 . Clinical trials, however, have strict inclusion and exclusion criteria, and a considerable number of patients do not fulfill them. For this reason, the outcomes of clinical trials are usually significantly better than in later common use of the drug. In our program, patients with low performance status and low life-expectancy or significant co-morbidity were included. Despite these inclusions, the results were surprisingly better than in the SIRIUS trial with a significant number of patients achieving therapeutic response, and with indisputable improvement in PFS and OS. The treatment was well tolerated and none of the patients quit the program due to toxicity. However, we need further tools to better define the group of patients who would profit from DARA monotherapy.
We acknowledge the very limited number of patients entering the program. However, the spectrum of patients including demographics, previous treatment and cytogenetics was very similar to that published in the SIRIUS trial though we had a larger number of high-risk patients including those with extramedullary disease. We had fewer less patients with previous carfilzomib pretreatment (21.4% vs 50% in the SIRIUS trial). Our results show that the effect of DARA in MM is indisputable. Several issues are still to be resolved including the long-term outcomes when DARA is used in earlier treatment lines, the unexpectedly good synergy of DARA and lenalidomide or possible down-regulation of CD38 and the occurrence of CD38-negative relapses after DARA as reported in our previous paper 18 .
CONCLUSION
We conclude that single agent daratumumab has significant efficacy in advanced multiple myeloma. The unique mechanism of action via immune-mediated mechanisms provides a novel therapeutic approach with effect in highly pre-treated refractory populations with myeloma clone resistant to other therapies. Even in an unselected real--world population (outside clinical trials) the treatment leads to high response rates as well as to fair prolongation of progression free and overall survival. Our results including response rates and PFS are even better than in the registration trial, confirming the safety and unique efficacy of the regimen. In patients who are refractory to proteasome inhibitors and IMiDs, who would be otherwise left for palliative care, DARA represents a chance for therapeutic response and improvement of both, survival and quality of life. Moreover, patients responding to DARA may recover sensitivity to other drugs, and could benefit from re-treatment or further treatment with other novel agents in the case of following relapse. The economic burden of the regimen is substantial. Nevertheless, our results confirm that the effectiveness of DARA and especially the impact on overall survival even in unselected advanced myeloma patients outweighs the economical impact of this treatment. Acknowledgement: Supported by the grant AZV 17-29343A, IGA-LF-2018-004 and MH CR -RVO (FNOl, 00098892). Author contributions: JM: manuscript writing, study design and participated in patient recruitment; JM, LP, VM, IS, AJ, TJ, TP, VS, RH: participated in patient recruitment at the 7 hematological centers in the Czech Republic; JM, VM, IS, AJ, TJ, RH: data analysis and critical revision; LB: statistical analysis.
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